Skip to content

Publishing of Nexstim Plc 2016 Full Year Results

17 February 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, will announce its full year results for the year ended 31 December 2016 in the morning of Monday 28 February 2017.

A conference call for analysts, investors and media will take place at 16:00 Finnish time (EET) on Monday 28 February 2017, hosted by Martin Jamieson, Chairman of the Board and CEO, and Mikko Karvinen, CFO, who will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:

Finland: +358 (0) 800 914672

Sweden: +46 (0) 20 089 6388

UK: +44 (0) 20 3003 2666

US: + 1 866 966 5335

Standard International: +44 (0) 20 3003 2666


The call Password is Nexstim



Martin Jamieson, Chairman and CEO

Further information is available on the website or by contacting:

Nexstim                                                                                                                                +447715163942

Martin Jamieson, Chairman and CEO                                                     


UB Securities Oy (Certified Adviser)                                                                              +358 (0)9 2538 0246

Citigate Dewe Rogerson                                                                                                 +44 (0)207 2821066

Katja Stout                                                                                                  


About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim’s shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit

Source: Nexstim